FY22 results for Australian Clinical Labs missed expectations and brokers await an uptick in non-covid testing
Megaport’s FY22 result highlighted significant metrics disclosed for the first time, underpinning broker views of a solid longer term growth story
Dedicated lung imaging pioneer 4D medical sees itself as a software company, with lots of future potential, including from the US military
Brokers set lower price targets for Nitro Software on lower growth expectations after a trading update surprised negatively
Micro-cap biotech Orthocell is aiming to emulate the successful growth story of Polynovo, nowadays capitalised at $1.1bn
Increasing frequency and intensity of catastrophic events is good news for Johns Lyng Group’s growth, as the company delivered a record half in catastrophe works revenue
Broker opinions vary widely on the outlook for Limeade after FY21 results highlighted a lack of organic growth but with emerging positive signs
Technology has entered schools and education, and there’s no turning back to pre-covid status quo
Bigger jackpots are feeding into higher growth numbers for Jumbo Interactive, negating creeping up costs
Lifestyle Communities remains on track for longer-term growth with the ageing population underpinning demand for its retirement accommodations